Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors

British Journal of Cancer

Volumn 78, Issue 6, 1998, Pages 745-751

  McDonald, A C ^a   Brown, R ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Apoptosis; Camptothecin; Cell cycle; Drug resistance; p53

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALANINE; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; PACLITAXEL; PROTEIN P53; TOPOTECAN; TRANSFERASE; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; CELL CYCLE; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HUMAN; HUMAN CELL; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0031684842     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.571     Document Type: Article

References (41)

1. Agarwal ML, Agarwal A, Taylor W and Stark GR (1995) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci 92: 8493-8497
2. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin ARM and Brown R (1996) Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumour cells. Cancer Res 56: 1374-1381
3. Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M and Rougier P (1995) CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A: 1283-1287
4. Barlogie B and Drewinko B (1978) Cell cycle stage-dependent induction of G2 phase arrest by different antitumour agents. Eur J Cancer 14: 741-745
5. Bates S and Vousden KH (1996) p53 in signalling checkpoint arrest or apoptosis. Current Opinion in Genetics and Development 6: 12-19
6. Brown R, Clugston C, Burns P, Edlin A, Vasey PA, Vojtesek B and Kaye SB (1993) Increased accumulation of p53 protein in cisplatin resistant cell lines. Int J Cancer 55: 678-684
7. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR and Bevilacqua G (1997) p53 alteration are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75: 230-235
8. Cotter TG, Glynn JM, Echeverri F and Green DR (1992) The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cell cycle. Anticancer Res 12: 773-780
9. Creemers GJ, Bolis G, Gore M, Scarfore G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J and Ten Bokkel Huinink WW (1996) Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14: 3056-3061
10. del Bino G, Skierski JS and Darzynkiewicz Z (1990) Diverse effects of camptothecin, an inhibitor of topoisomerase 1, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KGI) leukaemic cells. Cancer Res 50: 5746-5750
11. Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW and O'Connor PM (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830
12. Fritsche M, Haessler C and Brandner G (1993) Induction of nuclear accumulation of the tumour suppressor protein p53 by DNA damaging agents. Oncogene 8: 307-318
13. Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW and Pommier Y (1996) Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 56: 4430-4437
14. Gorczyca W, Gong J, Ardelt B, Traganos F and Darzynkiewicz (1993) The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumour agents. Cancer Res 53: 3186-3192
15. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF and Hamilton TC (1993) Cross resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cell lines. Cancer Res 53: 5225-5232
16. Hawkins DS, Demers GW and Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898
17. Hsiang YH and Liu LF (1988) Identification of mammalian DNA topoisomerase 1 as an intracellular target of the anti cancer drugs camptothecin. Cancer Res 48: 1722-1726
18. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
19. Ko LJ and Prives C (1996) p53: puzzle and paradigm. Gene Dev 10: 1054-1072
20. Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Orvis Adamo D, Davis P, Ognibene FP, Cunnion RE and Reed E (1994) Dose intense taxol: high response rate in patients with platinum resistant recurrent ovarian cancer. J Natl Cancer Inst 86: 18-24
21. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M and Kavanagh JJ (1996) Phase 2 study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14: 1552-1557
22. McIlwrath AJ, Vasey PA, Ross GM and Brown R (1994) Cell cycle arrest and radiosensitivity of human tumour cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 54: 3718-3722
23. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL (1991) Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389-393
24. Nelson WG and Kastan MB (1994) DNA strand breaks: the DNA template alterations that trigger p53 dependent DNA damage response pathways. Mol Cell Biol 14: 1815-1823
25. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I and Kohn KW (1993) Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53: 4776-4780
26. Pantazis P, Mendoza JT, Kozielski AJ, Natelson EA and Giovanella BC (1993) 9-Nitrocamptothecin delays growth of U-937 leukaemia tumours in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukaemia lines in vitro. Eur J Haematol 50: 81-89
27. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced Bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562
28. Potmesil M (1994) Camptothecins: fom bench research to hospital wards. Cancer Res 54: 1431-1439
29. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G and Zunino F (1996) A comparative study of p53 mutations, protein accumulation and response to cisplatin based chemotherapy in ovarian carcinoma. J Clin Oncol 56: 689-693
30. Shelling AN, Cooke IE and Ganesan TS (1995) The genetic analysis of ovarian cancer. Br J Cancer 72: 521-527
31. Slichenmeyer WJ, Nelson WG, Slebos RJ and Kastan MB (1993) Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 53: 4164-4168
32. Stewart N, Hicks GG, Paraskevas F and Mowat M (1995) Evidence for a second cell cycle block at G2/M by p53. Oncogene 10: 109-115
33. Takeuchi S, Takamizawa H, Takeda T, Okawa T, Tayama T, Noda K, Sugawa T, Sekiba K, Yakushiji M and Taguchi T (1991) Clinical study of CPT-11, camptothecin derivative, on gynaecological malignancy. Proc Am Soc Clin Oncol 10: 189
34. Takimoto CH and Arbuck SG (1996) The Camptothecins. In Cancer Chemotherapy and Biotherapy, Chabner BA and Longo DL (eds), pp. 463-484. Lippincott Raven: Philadelphia
35. ten Bokkel Huinik W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstom H, Coleman R, Fields SC and Heron J (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15: 2183-2193
36. 14Z/cyclin B. Cancer Res 52: 1823-1829
37. Vasey PA, Jones NA, Jenkins S, Dive C and Brown R (1996) Cisplatin. camptothecin and taxol sensitivities of cells with p53 associated multiagent resistance. Mol Pharmacol 50: 1536-1540
38. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW and Galloway DA (1996) Loss of normal p53 function confers sensitisation to taxol by increasing G2/M arrest and apoptosis. Nature Med 2: 72-79
39. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler KW, Vogelstein B and Williams J (1997) Cell-cycle arrest versus cell death in cancer therapy. Nature Med 3: 1034-1036
40. Wanders J, Bokkel Huinink WW, Heinrich B, Gore M, Calvert AH, Lehnert M, te Velde A and Verweij J (1996) Phase II studies with GI-147211 in 5 different tumour types - preliminary results. Ann Oncol 7(Suppl 1): 131
41. Young RC, Perez CA and Hoskins WJ (1993) Cancer of the ovary. In Cancer: Principles and Practice of Oncolgy, DeVita VT, Hellman S and Rosenberg SA (eds), pp. 1226-1263. JB Lippincott: Philadelphia